Cimzia (certolizumab pegol) is an injectable biologic medication used to treat seven inflammatory conditions, spanning autoimmune joint diseases, inflammatory bowel disease, and skin disorders. It belongs to a class of drugs called TNF blockers, which work by neutralizing a protein that drives inflammation throughout the body.
Conditions Cimzia Treats
Cimzia is FDA-approved for a broader range of inflammatory conditions than many people realize. Its approved uses include:
- Crohn’s disease in adults with moderately to severely active disease who haven’t responded well to conventional treatments
- Rheumatoid arthritis in adults with moderate to severe disease
- Psoriatic arthritis in adults with active disease
- Ankylosing spondylitis, a form of inflammatory arthritis that primarily affects the spine
- Non-radiographic axial spondyloarthritis, a condition with spinal inflammation that doesn’t yet show up on X-rays but has objective signs of inflammation
- Plaque psoriasis in adults with moderate to severe disease who are candidates for systemic therapy or light therapy
- Polyarticular juvenile idiopathic arthritis in children aged 2 and older
The common thread across all these conditions is overactive inflammation driven by a molecule called tumor necrosis factor alpha (TNF-alpha). In each of these diseases, the immune system produces too much TNF-alpha, which triggers pain, swelling, joint damage, or skin lesions depending on where the inflammation occurs.
How Cimzia Works
Cimzia is a TNF blocker, meaning it binds to TNF-alpha and prevents it from triggering inflammatory responses. Several other biologics do this too, but Cimzia has a structural difference that sets it apart: it’s an antibody fragment rather than a full antibody.
Most TNF blockers are complete antibodies with a region called the Fc portion, which interacts with immune cells in ways beyond just blocking TNF. Cimzia lacks this Fc portion entirely. Instead, it’s a smaller antibody fragment attached to two chains of polyethylene glycol (PEG), a molecule that helps it stay in the body longer. This PEGylated design gives it a longer half-life while changing how it interacts with the immune system compared to full-antibody TNF blockers. The absence of the Fc portion also has important implications for pregnancy, discussed below.
Pregnancy and Breastfeeding
One of Cimzia’s most notable features is its minimal transfer across the placenta. Because it lacks the Fc portion that other antibodies use to cross the placental barrier, very little of the drug reaches the fetus. In a study of pregnant women at 30 weeks of gestation or later, 13 out of 14 infants had no detectable Cimzia levels in their blood at birth. Umbilical cord blood showed similar results, with 12 out of 15 samples having no measurable drug levels.
This is a meaningful distinction from other TNF blockers. Full-antibody biologics are actively transported across the placenta during the third trimester, exposing the fetus to the drug. The data on Cimzia suggest that women who need ongoing TNF-blocker therapy during pregnancy can continue treatment without significant fetal drug exposure. For women with active Crohn’s disease, rheumatoid arthritis, or other inflammatory conditions, uncontrolled disease during pregnancy carries its own risks, making this a practical consideration.
How Cimzia Is Given
Cimzia is administered as a subcutaneous injection, meaning it goes just under the skin in the abdomen or upper thigh. It comes in two forms: a prefilled syringe designed for self-injection at home, and a lyophilized (freeze-dried) powder that requires reconstitution and is typically given by a healthcare provider.
For Crohn’s disease, treatment starts with a loading phase: 400 mg (split into two 200 mg injections) at the first visit, then again at weeks 2 and 4. After that initial period, patients who respond continue with 400 mg every four weeks as ongoing maintenance. The loading dose schedule helps build up therapeutic drug levels quickly, which matters when someone is dealing with active symptoms.
The medication needs to be refrigerated at 2 to 8°C (roughly standard refrigerator temperature) but should be brought to room temperature before injection for comfort. If using the powder form, once reconstituted it can be stored in the refrigerator for up to 24 hours before use. It should never be frozen.
Side Effects and Risks
The most frequently reported side effects in clinical trials were upper respiratory infections (18% of patients), rash (9%), and urinary tract infections (8%). These are consistent with what you’d expect from a medication that partially suppresses immune function.
Cimzia carries a boxed warning, the FDA’s most serious safety alert, for two categories of risk. The first is serious infections. Because the drug suppresses part of the immune system, it can allow infections to take hold that a healthy immune system would normally control. These include tuberculosis (including reactivation of latent TB that was previously dormant), invasive fungal infections, and other opportunistic infections. The risk increases for patients who are also taking other immune-suppressing medications like methotrexate or corticosteroids. Doctors typically screen for latent tuberculosis before starting treatment.
The second boxed warning concerns malignancy. Lymphoma and other cancers, some fatal, have been reported in children and adolescents treated with TNF blockers as a class. This risk is important context for the pediatric juvenile idiopathic arthritis indication, though the overall incidence remains low.
Where Cimzia Fits Among TNF Blockers
Cimzia is one of several TNF blockers available, and its unique antibody-fragment structure creates some trade-offs. Its minimal placental transfer makes it a preferred option for women of childbearing age who may need biologic therapy through pregnancy. Its PEGylated design allows for every-four-week dosing during maintenance, which is less frequent than some alternatives.
However, the lack of an Fc portion may affect its performance in certain conditions. Some evidence suggests that full-antibody TNF blockers may be more effective for inflammatory bowel diseases specifically, though head-to-head comparative trials have not been performed. For joint and skin conditions, Cimzia has demonstrated strong efficacy in its own clinical trials, and the choice between TNF blockers often comes down to individual response, insurance coverage, and specific patient factors like pregnancy planning.